TRANCE/TNFSF11/RANK L Antibody (8A7B9) - BSA Free

Flow Cytometry: TRANCE/TNFSF11/RANK L Antibody (8A7B9) - BSA Free [NBP2-61813]

Flow Cytometry: TRANCE/TNFSF11/RANK L Antibody (8A7B9) [NBP2-61813] - Analysis of Hela cells using TNFSF11 mouse mAb (green) and negative control (red).

Western Blot: TRANCE/TNFSF11/RANK L Antibody (8A7B9)BSA Free [NBP2-61813]

Western Blot: TRANCE/TNFSF11/RANK L Antibody (8A7B9) [NBP2-61813] - Analysis using TNFSF11 mAb against human TNFSF11 (AA: 74-308) recombinant protein. (Expected MW is 52.6 kDa)

Western Blot: TRANCE/TNFSF11/RANK L Antibody (8A7B9)BSA Free [NBP2-61813]

Western Blot: TRANCE/TNFSF11/RANK L Antibody (8A7B9) [NBP2-61813] - Analysis using TNFSF11 mouse mAb against COS7 (1), Hela (2), U937 (3), HL-60 (4), Raji (5), Ramos (6), Jurkat (7), and SW480 (8) cell lysate.

ELISA: TRANCE/TNFSF11/RANK L Antibody (8A7B9) - BSA Free [NBP2-61813]

ELISA: TRANCE/TNFSF11/RANK L Antibody (8A7B9) [NBP2-61813] - Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)

Western Blot: TRANCE/TNFSF11/RANK L Antibody (8A7B9) - BSA Free [NBP2-61813] -

An anti-RANKL treatment increases SERCA activity and modulates intracellular calcium homeostasis regulators in the dystrophic heart. SERCA activity (A), western blot analyses of SERCA2a (B), phospholamban (PLN) (C), Ryanodine (RyR) (D), and FKBP12 (E) protein levels in hearts from WT, PBS-injected mdx, and anti-RANKL-treated mdx mice. Results are expressed as means +/- SEM (* p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001). Shown are an analysis of variance two-way ANOVA with a Bonferroni correction (A) and an analysis of variance one-way ANOVA with a Tuckey correction for western blots (B–E). N = 11 for WT, mdx-PBS, and mdx-anti-RANKL for SERCA activity (A); n = 3–8 for WT, mdx-PBS, and mdx-anti-RANKL for Western blots (B–E). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/37296659), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: TRANCE/TNFSF11/RANK L Antibody (8A7B9) - BSA Free [NBP2-61813] -

An anti-RANKL treatment reduces the cardiomyocyte surface and inhibits cardiac hypertrophy mediators in dystrophic mice. The heart tissues were sectioned and were incubated with laminin (green), rhodamine-phalloidin (red), and DAPI (blue) markers to label the cardiomyocyte membrane, F-actin filaments, and nuclei, respectively, at 20× magnification (A). The cardiomyocyte mean cross-sectional area (CSA) (A) and CSA distribution (B). Western blot analyses of pNF kappa B (C), NF kappa B (D), pPI3K (E), and PI3K (F) protein levels. The scale bar in A represents 0.05 mm. Results are expressed as means +/- SEM (* p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001). Shown are an analysis of variance one-way ANOVA with a Tuckey correction for the CSA and western blots (A,D–F), and an analysis of variance two-way ANOVA with a Bonferroni correction for a distribution analysis (B). N = 3 for WT, n = 6 for mdx-PBS, and n = 9 for mdx-anti-RANKL for the cardiomyocyte CSA (A) and distribution (B). N = 3–6 for WT, n = 5–10 for mdx-PBS, and n = 5–9 for mdx-anti-RANKL for the western blots (C–F). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/37296659), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: TRANCE/TNFSF11/RANK L Antibody (8A7B9) - BSA Free [NBP2-61813] -

An anti-RANKL treatment reduces the cardiomyocyte surface and inhibits cardiac hypertrophy mediators in dystrophic mice. The heart tissues were sectioned and were incubated with laminin (green), rhodamine-phalloidin (red), and DAPI (blue) markers to label the cardiomyocyte membrane, F-actin filaments, and nuclei, respectively, at 20× magnification (A). The cardiomyocyte mean cross-sectional area (CSA) (A) and CSA distribution (B). Western blot analyses of pNF kappa B (C), NF kappa B (D), pPI3K (E), and PI3K (F) protein levels. The scale bar in A represents 0.05 mm. Results are expressed as means +/- SEM (* p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001). Shown are an analysis of variance one-way ANOVA with a Tuckey correction for the CSA and western blots (A,D–F), and an analysis of variance two-way ANOVA with a Bonferroni correction for a distribution analysis (B). N = 3 for WT, n = 6 for mdx-PBS, and n = 9 for mdx-anti-RANKL for the cardiomyocyte CSA (A) and distribution (B). N = 3–6 for WT, n = 5–10 for mdx-PBS, and n = 5–9 for mdx-anti-RANKL for the western blots (C–F). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/37296659), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: TRANCE/TNFSF11/RANK L Antibody (8A7B9) - BSA Free [NBP2-61813] -

An anti-RANKL treatment reduces the cardiomyocyte surface and inhibits cardiac hypertrophy mediators in dystrophic mice. The heart tissues were sectioned and were incubated with laminin (green), rhodamine-phalloidin (red), and DAPI (blue) markers to label the cardiomyocyte membrane, F-actin filaments, and nuclei, respectively, at 20× magnification (A). The cardiomyocyte mean cross-sectional area (CSA) (A) and CSA distribution (B). Western blot analyses of pNF kappa B (C), NF kappa B (D), pPI3K (E), and PI3K (F) protein levels. The scale bar in A represents 0.05 mm. Results are expressed as means +/- SEM (* p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001). Shown are an analysis of variance one-way ANOVA with a Tuckey correction for the CSA and western blots (A,D–F), and an analysis of variance two-way ANOVA with a Bonferroni correction for a distribution analysis (B). N = 3 for WT, n = 6 for mdx-PBS, and n = 9 for mdx-anti-RANKL for the cardiomyocyte CSA (A) and distribution (B). N = 3–6 for WT, n = 5–10 for mdx-PBS, and n = 5–9 for mdx-anti-RANKL for the western blots (C–F). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/37296659), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: TRANCE/TNFSF11/RANK L Antibody (8A7B9) - BSA Free [NBP2-61813] -

An anti-RANKL treatment increases SERCA activity and modulates intracellular calcium homeostasis regulators in the dystrophic heart. SERCA activity (A), western blot analyses of SERCA2a (B), phospholamban (PLN) (C), Ryanodine (RyR) (D), and FKBP12 (E) protein levels in hearts from WT, PBS-injected mdx, and anti-RANKL-treated mdx mice. Results are expressed as means +/- SEM (* p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001). Shown are an analysis of variance two-way ANOVA with a Bonferroni correction (A) and an analysis of variance one-way ANOVA with a Tuckey correction for western blots (B–E). N = 11 for WT, mdx-PBS, and mdx-anti-RANKL for SERCA activity (A); n = 3–8 for WT, mdx-PBS, and mdx-anti-RANKL for Western blots (B–E). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/37296659), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: TRANCE/TNFSF11/RANK L Antibody (8A7B9) - BSA Free [NBP2-61813] -

An anti-RANKL treatment reduces the cardiomyocyte surface and inhibits cardiac hypertrophy mediators in dystrophic mice. The heart tissues were sectioned and were incubated with laminin (green), rhodamine-phalloidin (red), and DAPI (blue) markers to label the cardiomyocyte membrane, F-actin filaments, and nuclei, respectively, at 20× magnification (A). The cardiomyocyte mean cross-sectional area (CSA) (A) and CSA distribution (B). Western blot analyses of pNF kappa B (C), NF kappa B (D), pPI3K (E), and PI3K (F) protein levels. The scale bar in A represents 0.05 mm. Results are expressed as means +/- SEM (* p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001). Shown are an analysis of variance one-way ANOVA with a Tuckey correction for the CSA and western blots (A,D–F), and an analysis of variance two-way ANOVA with a Bonferroni correction for a distribution analysis (B). N = 3 for WT, n = 6 for mdx-PBS, and n = 9 for mdx-anti-RANKL for the cardiomyocyte CSA (A) and distribution (B). N = 3–6 for WT, n = 5–10 for mdx-PBS, and n = 5–9 for mdx-anti-RANKL for the western blots (C–F). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/37296659), licensed under a CC-BY license. Not internally tested by Novus Biologicals.